Universidade do Grande Rio (UNIGRANRIO); Centro Universitário Serra dos Órgãos (UNIFESO).
Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP).
J Appl Oral Sci. 2020 Dec 18;29:e20200568. doi: 10.1590/1678-7757-2020-0568. eCollection 2020.
The aim of this study is to evaluate the new bone and connective tissue formation and the biomaterial remaining after maxillary sinus bone augmentation using 5 different bone substitutes. The osteocalcin immunolabeling was performed to demonstrate their calcification and the possibility of receiving dental implants.
40 patients underwent maxillary sinus bone augmentation and were divided in 5 groups: Group 1 with 8 maxillary sinuses were grafted with autogenous bone graft (AB); Group 2 with 8 maxillary sinuses grafted with bioactive glass (BG); Group 3 with 8 maxillary sinuses grafted with bioactive glass added to autogenous bone graft (BG + AB) 1:1; Group 4 with 8 maxillary sinuses grafted with Bio-Oss (BO) and Group 5 with 8 maxillary sinuses grafted with Bio-Oss added to autogenous bone graft (BO + AB) 1:1.
In group AB, 37.8% of bone was formed in the pristine bone region, 38.1% in the intermediate and 44.5% in the apical region. In group BG, 43.6% was formed in the pristine bone, 37% in the intermediate and 49.3% in the apical region. In group BG + AB 1:1, 39.0% was formed in the pristine bone region, 34.8% in the intermediate and 36.8% in apical region. In group BO, 33.4% was formed in the pristine bone, 32.5% in the intermediate and 34.3% in the apical region. In group BO + AB 1:1, 32.8% was formed in the pristine bone, 36.1% in intermediate and 27.8% in the apical regions. The immunolabeling for osteocalcin showed an intensive staining for all groups, which could demonstrate the calcification of the bone formed.
This study showed that the groups evaluated formed a suitable lamellar bone in the maxillary sinus reconstruction after six months of bone healing, thus being indicated to receive dental implants.
本研究旨在评估使用 5 种不同骨替代物进行上颌窦骨增量后新骨和结缔组织的形成以及生物材料的残留情况。通过骨钙素免疫标记来证明其钙化和接受牙种植体的可能性。
40 例患者接受了上颌窦骨增量，分为 5 组：第 1 组 8 个上颌窦用自体骨移植物（AB）移植；第 2 组 8 个上颌窦用生物活性玻璃（BG）移植；第 3 组 8 个上颌窦用 1:1 的自体骨移植物和生物活性玻璃（BG+AB）移植；第 4 组 8 个上颌窦用 Bio-Oss（BO）移植；第 5 组 8 个上颌窦用 1:1 的自体骨移植物和 Bio-Oss（BO+AB）移植。
AB 组在原始骨区形成 37.8%的骨，在中间区形成 38.1%，在根尖区形成 44.5%。BG 组在原始骨区形成 43.6%的骨，在中间区形成 37%，在根尖区形成 49.3%。BG+AB 1:1 组在原始骨区形成 39.0%的骨，在中间区形成 34.8%，在根尖区形成 36.8%。BO 组在原始骨区形成 33.4%的骨，在中间区形成 32.5%，在根尖区形成 34.3%。BO+AB 1:1 组在原始骨区形成 32.8%的骨，在中间区形成 36.1%，在根尖区形成 27.8%。骨钙素免疫标记显示所有组均呈强染色，可证明形成的骨的钙化。
本研究表明，在骨愈合后 6 个月的上颌窦重建中，评估的各组均形成了合适的板层骨，因此可考虑植入牙种植体。
